Lorukafusp alfa

N/A

Report date: 2025/04/20 20:00:03

Base Information

Drug NameLorukafusp alfa
Drug Alias NameLorukafusp alfa - Apeiron BiologicsAnti-ganglioside-GD2-antibody-interleukin-2-fusion-proteinMonoclonal antibody ch14.18 interleukin-2 fusion proteinAPN-301hu14.18IL2 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor agonistsDisialoganglioside GD2 inhibitors
TargetsInterleukin-2 receptorDisialoganglioside GD2
Therapy Area/IndicationsSkin MelanomaSolid tumoursMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLexigen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Wisconsin-Madison
Inactive CompaniesNational Cancer Institute
Active IndicationsMelanoma
Inactive IndicationsSkin MelanomaSolid tumoursNeuroblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A